Movement Alert|ImmunityBio Intraday Decline 5.58% in Regular Trading, Trading at $8.34

Market Focus07-10

On July 10, ImmunityBio fell 5.58% in regular trading, trading at $8.34 USD/share, with Turnover of $12.05 million.

Within the Biotechnology sector where ImmunityBio belongs, the sector was broadly under pressure. Among individual stocks, Moderna down 7.61%, Ionis Pharmaceuticals down 7.42%, Argenx SE down 2.76%, AbbVie down 0.6%, Alnylam Pharmaceuticals up 0.16%.

ImmunityBio is a clinical-stage biotechnology company engaged in developing next-generation immune and cell therapies to enhance the natural immune system. Its core product Anktiva has been approved in 33 countries for the treatment of bladder cancer and lung cancer.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment